The Report HPV Testing And Pap Test Market Analysis by Test Type (HPV Test, Pap Test), By
Application (Cervical Cancer Screening, Vaginal Cancer Screening), By End-user
(Point-of-care, Central laboratories) And Segment Forecasts To 2024
The global human papillomavirus (HPV) testing
and pap test market are expected to reach USD 5.6 billion by 2024,
according to a new report by Grand View Research Inc.The market is majorly
driven by the increasing number of cervical cancer cases, government
initiatives, and the heightened awareness amongst women about cervical cancer.
For instance, the CDC advocates cervical cancer screening tests for women above
the age of 30 as it was found that the cervical cancers are rare in the age
group, 20-30 years (2 in 100,000) as compared to the older age groups (16 in
100,000).
In
addition to carrying out awareness campaigns, the government and key industrial
players are providing funding to universities for the development of enhanced
technologies to facilitate effective screening, which would mitigate the
incidence of late-stage cervical cancer. In this direction,in April 2014, the
FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV
test (Roche Molecular Systems), as a primary screening test.
A
study conducted by the scientists of Hologic, Inc. and University of Pittsburgh
Medical Center hasshownthe importance of combined testing (HPV and Pap) stating
that the Paptest identifies cellular abnormalities and the HPV test detects
suspicious viruses, hence improving the efficiency and providing the best
results that are cost-effective and convenient to the patients.
Access Research Report of HPV Testing And Pap Test Market @ www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market
Further key findings
from the report suggest:
· The cervical cancer screening segment dominated the
market in 2015 owing to the introduction of advanced technologies for the
screening and detection of cervical cancer. For instance, in May 2016,Hologic
Inc. determined that HPV and Pap co-testing was the most effective in the
screening of cervical cancer.
· The laboratories segment dominated the HAV and Pap test
market in 2015 owing to the increased performance in the diagnosis of cervical
cancer cases. As per the CDC statistics, approximately 21.7 million tests were
performed in the U.S.; hence,the hospitalssegmentis expected to witnessa rapid
growthin the coming years due to the increasing number of diagnostic tests
performed in-house and also the availability of advanced technologies.
· In 2015, North America held the largest share in terms of
revenue owing to the continual introduction ofinnovated technologies to improve
patient care and diagnosis. In addition, the high number of positive cases
being detected,along with the rising death toll (i.e., 2.6 in 1,00,000), has
compelled the government to conduct awareness programmes about the early
diagnosis and treatment of cervical cancer, which is a key factor for the large
market share.
· In April 2014, the FDA approved the use of the HPV DNA
test, also referred to as the Cobas HPV test. Roche introduced a test that
detectsthe DNAsequence of cancer-causing high-risk HPVs. It provides
information regardingpatients’ risk of developing cervical cancer. The Cobas
HPV test is used to specifically identify HPV 16 and HPV 18as well as12 other
high-risk HPVs from the cervical cell sample in women older than 25 years of
age.
· AsiaPacific is expected to grow at a high CAGR in the
coming years. As per the cancer council, 61% of the Australian women are
screened for cervical cancer every two years, out of which around 26% who have
been detected throughthe normal Pap test undergo an early re-screening more
often than the recommended two years of interval.
· Some key players in the market are QiagenN. V., Hologic,
Inc., Roche Holding AG, Abbott Laboratories, and Becton, Dickinson and
Company.These market players are in the process of introducing tests to change
the traditional methods of individual HPV and Pap tests and introducenewer
techniques or devices to improve the efficiency and convenience.
· For instance, in February 2016, Quest acquiredClinical
Laboratory Partner’s outreach laboratory service business. This acquisition is
expected to provide the patients a broader service network with better quality,
affordability, and convenience.
Grand View Research has segmented the global HPV testing
and Pap test market on the basis of type, application, end-use, and
regions:
HPV Testing and Pap Test
Outlook by Type (Revenue, USD Million, 2013 - 2024)
·
Pap Test
·
HPV Test
HPV Testing and Pap Test
Application Outlook (Revenue, USD Million, 2013 - 2024)
·
Cervical Cancer
·
Vaginal Cancer
HPV Testing and Pap Test
End-use Outlook (Revenue, USD Million, 2013 - 2024)
·
Point-of-Care
·
Central Laboratories
·
Others
HPV Testing and Pap Test
Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o U.S.
o Canada
·
Europe
o UK
o Germany
o Rest
of Europe
·
Asia Pacific
o India
o Japan
o China
o Rest
of Asia Pacific
·
Latin America
o Brazil
o Rest
of Latin America
·
MEA
o South
Africa
Access
Press Release of HPV Testing And Pap Test
Market @ www.grandviewresearch.com/press-release/global-hpv-test-pap-test-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
